Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-27 | Gail M. Farfel, Ph.D. (1) 56 Director ... (1) Member of the Compensation Committee ... Director Compensation for Fiscal 2019 Gail M. Farfel, Ph.D 32,605 Fees Earned or Paid in Cash ($) 30,170 Option Awards ($) — All Other Compensation ($) 62,775 Total ($) |
| 2021-04-23 | Gail M. Farfel, Ph.D. has served as a director since April 2019. ... Dr. Farfel’s pharmaceutical industry experience relating to executive management, strategic planning, medical and scientific expertise and pharmaceutical industry experience as it relates to drug development and regulatory affairs are among the qualifications she brings to the Board and her service as a Director of the Company. |
| 2022-04-25 | Gail M. Farfel, Ph.D. has served on our Board of Directors since April 2019. ... At the end of the last fiscal year, the Research and Development Committee was composed of Mohammad Azab, Terrence F. Blaschke and Gail M. Farfel. |
| 2023-04-27 | Gail M. Farfel, Ph.D. has served on our Board of Directors since April 2019. ... At the end of the last fiscal year, the Research and Development Committee was composed of Mohammad Azab, Terrence F. Blaschke and Gail M. Farfel. ... Director Compensation for Fiscal 2022: Gail M. Farfel, Ph.D. Fees Earned or Paid in Cash ($) 47,500, Option Awards ($) 23,150, Total ($) 70,650. |
| 2024-08-12 | Gail M. Farfel, Ph.D. has served on our Board of Directors since April 2019. Dr. Farfel served as the Chief Executive Officer of ProMIS Neurosciences Inc. from September 2022 through December 2023. Dr. Farfel’s pharmaceutical industry experience relating to executive management, strategic planning, medical and scientific expertise and pharmaceutical industry experience as it relates to drug development and regulatory affairs are among the qualifications she brings to our Board of Directors. Director Compensation for Fiscal 2023 shows cash fees of $47,500 and option awards valued at $23,115, totaling $70,615. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22